Invitae Corp. (NYSE:NVTA) saw its stock flying high June 22 on the news of its agreement to buy Archerdx Inc., with an eye toward enhancing cancer genetics and precision oncology. Investors appear to approve of the deal, with the company’s stock closing at $27.05, up $8.34 or 44.58%.
Keeping you up to date on recent developments in cardiology, including: App helps to detect fluid in the lungs in HF patients; Connection between opioids and heart surgery; 3D map of heart’s neurons.
Keeping you up to date on recent developments in cardiology, including: Assessing who’s at risk for heart rhythm disorders; Rewiring the heart to prevent recurrent fainting spells; Understanding link between COVID-19, cardiovascular diseases.
Keeping you up to date on recent developments in cardiology, including: Stroke protection effects like night and day; Blood pressure meds help range of patients when taken as prescribed; Test IDs undetected blood clots in COVID-19 patients.
Brisbane, Calif.-based Caredx Inc., which is aiming to transplant patient outcomes, saw the presentation of a host of data at the recent American Transplant Congress annual meeting.
Westport, Conn.-based Lumendi LLC revealed that the first endoscopic appendectomy has taken place using its Dilumen Endolumenal Interventional Platform (EIP). The procedure represents a change from traditional appendectomies, which are performed through open or laparoscopic surgery, requiring an incision of the abdominal wall.
Exact Sciences Corp., of Madison, Wis., detailed three studies of the Oncotype Dx Breast Recurrence Score test during the virtual 2020 American Society of Clinical Oncology Annual Meeting.
Hayward, Calif.-based Reflexion Medical Inc. reported a clinical collaboration with Merck & Co. Inc., of Kenilworth, N.J., to evaluate the safety and efficacy of Keytruda (pembrolizumab) in combination with biology-guided radiotherapy (BgRT) in multiple late-stage cancers. The goal is to establish whether treating multiple tumors with BgRT, a novel external beam radiotherapy treatment (EBRT) modality in development, is safe and amplifies Keytruda’s therapeutic effect.
Keeping you up to date on recent developments in cardiology, including: iPSC microtissue gives clues to heart disease; Two paths for helping patients with heart stents; COVID-19 hits stroke patients.
Like many companies, Rewalk Robotics Ltd. saw its financials hit by the COVID-19 pandemic. It revealed May 28 that its total revenue for its first quarter fell to $0.8 million, down from $1.6 million during the same period last year. The company, which focuses on solutions that give gait training and mobility for individuals with lower limb disabilities, acknowledged the effects of the pandemic, noting that several Rewalk Personal 6.0 devices were not delivered as a result.
